{
  "pmcid": "3528899",
  "sha256": "1fcf414917891a2351aa5bce17d9f93000bde8013ac967d48f0e81432bd7e72e",
  "timestamp_utc": "2025-11-09T23:48:43.919996+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 16.02439560439561,
    "reading_ease": 13.25346153846155,
    "word_count": 260
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Intraosseous Versus Systemic Administration of Cefazolin in Primary Total Knee Arthroplasty: A Randomised Controlled Trial"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Participants were randomly assigned to two groups"
      },
      "Participants": {
        "score": 2,
        "evidence": "22 patients undergoing primary TKA"
      },
      "Intervention": {
        "score": 2,
        "evidence": "Group 1 (n=11) received 1 g cefazolin systemically... Group 2 (n=11) received 1 g cefazolin intraosseously"
      },
      "Objective": {
        "score": 1,
        "evidence": "This study aims to compare the tissue concentrations of cefazolin achieved through systemic versus regional intraosseous administration."
      },
      "Method_Outcome": {
        "score": 1,
        "evidence": "antibiotic concentrations were measured using high-performance liquid chromatography"
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was computer-generated, and allocation was concealed using sealed envelopes."
      },
      "Blinding": {
        "score": 0,
        "evidence": "Blinding details were not specified."
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "22 patients undergoing primary TKA"
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "The mean tissue concentration of cefazolin in subcutaneous fat was 186 ug/g in the intraosseous group and 11 ug/g in the systemic group."
      },
      "Harms": {
        "score": 1,
        "evidence": "No adverse events were reported in either group."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Trial registration and funding information were not provided."
      },
      "Funding": {
        "score": 0,
        "evidence": "Trial registration and funding information were not provided."
      }
    },
    "total_score": 14,
    "max_score": 25
  }
}